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Abstract
Background: A progressive development of hepatic steatosis with an increase in the lipid
hepatocyte content and the formation of megamitochondria have been demonstrated in rats with
prehepatic portal hypertension. The aim of this study is to verify the existence of liver and serum
lipid metabolism impairments in rats with long-term (2 years) portal hypertension.
Methods: Male Wistar rats: Control (n = 10) and with prehepatic portal hypertension by triple
partial portal vein ligation (n = 9) were used. Liver content of Triglycerides (TG), phospholipids
(PL) and cholesterol and serum cholesterol, lipoproteins (HDL and LDL), TG, glucose and Lipid
Binding Protein (LBP) were assayed with specific colorimetric commercial kits. Serum levels of
insulin and somatostatin were assayed by RIA.
Results: The liver content of TG (6.30 ± 1.95 vs. 4.17 ± 0.59 μg/ml; p < 0.01) and cholesterol (1.48
± 0.15 vs. 1.10 ± 0.13 μg/ml; p < 0.001) increased in rats with portal hypertension. The serum levels
of cholesterol (97.00+26.02 vs. 114.78 ± 37.72 mg/dl), TG (153.41 ± 80.39 vs. 324.39 ± 134.9 mg/
dl; p < 0.01), HDL (20.45 ± 5.14 vs. 55.15 ± 17.47 mg/dl; p < 0.001) and somatostatin (1.32 ± 0.31
vs. 1.59 +0.37 mg/dl) decreased, whereas LDL (37.83 ± 15.39 vs. 16.77 ± 6.81 mg/dl; p < 0.001) and
LBP (308.47 ± 194.53 vs. 60.27 ± 42.96 ng/ml; p < 0.001) increased.
Conclusion: Portal hypertension in the rat presents changes in the lipid and carbohydrate
metabolisms similar to those produced in chronic inflammatory conditions and sepsis in humans.
These underlying alterations could be involved in the development of hepatic steatosis and,
therefore, in those described in the metabolic syndrome in humans.
Background
Portal Hypertension (PH) is a clinical syndrome defined
by a pathological increase in blood pressure in the portal
system [1,2]. It is one of the most frequent and serious
complications of chronic liver disease [1,2]. In prehepatic
PH there is no underlying liver disease [3] and thus its
Published: 13 February 2008
Lipids in Health and Disease 2008, 7:4 doi:10.1186/1476-511X-7-4
Received: 25 October 2007
Accepted: 13 February 2008
This article is available from: http://www.lipidworld.com/content/7/1/4
© 2008 Sánchez-Patán et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 10
(page number not for citation purposes)
Lipids in Health and Disease 2008, 7:4 http://www.lipidworld.com/content/7/1/4complications are related to the obstruction to the portal
flow [1,2]. These alterations are splanchnic, like the devel-
opment of portosystemic vessels, splenomegaly or portal
hypertensive enteropathy, and extrasplanchnic, such as
encephalopathy or hepato-pulmonary syndrome [2]. The
partial portal vein ligation (PVL) in the rat has widely
been used for the experimental study of PH since it has
traditionally been accepted that portal vein stenosis does
not induce liver disease [4,5].
However, we have shown that prehepatic PH by triple par-
tial portal vein ligation (TPVL) in the rat produces micro-
vesicular hepatocytic fatty infiltration with
megamitochondria and an impairment of the liver lipid
metabolism in the short (1 month) and long-term (1
year) [6-8]. Triglycerides, diacylglicerol and cholesterol
increased in the liver [8]. Liver steatosis was also described
in rats with PH [9] and this association was already sug-
gested in humans over 30 years ago [10].
PH is, essentially, a type of vascular pathology related to
the action of mechanical energy on splanchnic venous cir-
culation. Mechanical energy may act in the vascular
endothelium as a stressor stimulus which triggers an
inflammatory response [11]. We have thus shown that in
portal hypertensive-rats, splanchnic and systemic inflam-
matory changes are developed [12]. Portal hypertensive
enteropathy mediated by mast cells, among other factors,
[13] was reduced by the prophylactic administration of
anti-inflammatory drugs, like Budesonide and Ketotifen
[14,15]. Pro-and anti-inflammatory mediators, like NO,
TNF-α, IL-1β, CO and IL-10, are released from the gut and
the liver [16]. Endocrine impairments, such as increased
serum levels of corticosterone and Triiodothyronine (T3),
Thyroxin (T4) and decreased levels of Prolactin [17] are
also shown in this experimental model. We have, there-
fore, proposed an inflammatory etiopathogenic hypo-
thesis of PH [11]. Inflammation of the splanchnic system
could be the key player that drives the essential nature of
the complications of PH.
Although other authors described the disease as early as
the 1950s [18], in 1980 Ludwig called it nonalcoholic
steatohepatitis (NASH), what we now consider to be one
of the manifestations of the broader nonalcoholic fatty
liver disease (NAFLD) spectrum [18,19]. Although a quar-
ter of a century later, we know that the pathogenesis of
NAFLD is complex and multifactorial. Clues to its com-
prehension were already suggested by features highlighted
by Ludwig: insulin resistance (IR) (obesity, diabetes and
gallstones) fatty-inflammatory liver changes (now consid-
ered components of the endocrine system (diabetes, thy-
roid dysfunction and prevalence in females) [19].
Metabolic Syndrome (MS) is defined as the presence of at
least three of the following changes: blood hypertension,
central obesity, fasting hyperglycemia, hypertriglyceri-
demia and reduced high density lipoprotein (HDL) [18].
A common pathophysiological feature in this syndrome is
insulin resistance [20]. However, an array of other endo-
crine alterations, like hypopituitarism, decreased thyroid
and sex hormones, increased Glucocorticoids, the activa-
tion of Renin Angiotensin Aldosterone System (RAAS)
and changes in adipokines are shown [19]. So, the link
between IR, sub-clinical inflammation, MS and NAFLD is
now widely accepted [19,20]. Patients with NAFLD suffer
a low-grade systemic inflammatory state associated with
NAFLD [21,22].
Taking all these factors in account, we can speculate that
prehepatic PH in the rat could induce a type of Metabolic
Syndrome related to a chronic inflammatory response. In
order to verify this hypothesis we have measured the liver
content of Cholesterol, Triglycerides and Phospholipids
and the serum levels of Cholesterol, Triglycerides, low-
density lipoprotein (LDL), HDL, Lipid binding Protein
(LBP), Glucose, Insulin and Somatostatin in rats with
long-term (nearly 2 years after the operation) PH.
Results
Splanchnic changes related to portal hypertension
The existence of portal hyperpressure in the long-term (22
months) in this experimental model of triple partial por-
tal vein ligation was confirmed by the development of
portal hyperpressure, mesenteric venous vasculopathy,
splenomegaly and portal-systemic collateral circulation.
Portal pressure
The portal pressure (PP) in portal hypertensive-rats was
higher (p = 0.004) than in sham-operated rats (Table 1).
Mesenteric venous vasculopathy
Rats with portal hypertension showed macroscopic
mesenteric vasculopathy, with dilation and tortuosity of
the superior mesenteric vein and of its branches, in 77.7%
(n = 7) of the animals. In 5 rats it was spontaneous (Grade
II) while in 2 animals it was related to the clamping of the
superior mesenteric vein (Grade I).
Splenomegaly
All the animals with portal hypertension showed a higher
spleen weight when compared to body weight (p =
0.0001) (Table 1).
Collateral circulation
Interestingly enough, 22 months after the intervention all
the rats presented portosystemic collateral circulation
(splenorenal in 100%, hemorrhoidal in 66.6% and
paraesophageal in 33.3%). Portohepatic collateral vessels
through the hepatic accessory vein were shown in 33.3%
of the animals.Page 2 of 10
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Liver weight was lesser (p = 0.0001) in portal hyperten-
sive-rats in relationship to sham-operated, but although
the liver atrophy was apparent, when LW was related to
body weight (LW/BW), the difference was not statistically
significant. A discrete redistribution was produced in the
liver mass between the liver lobes, since the weight of the
posterior lobes (middle and left lateral) decreased
whereas the weight of the anterior lobes (right lateral and
caudate) increased (Table 1).
Testicular weight
Testes weight was lesser (p = 0.008) in rats with PH, but
when compared to body weight (TW/BW), the results
were similar in both group of rats (Table 1). So, PH in the
long-term does not produce testes atrophy.
Body Weight
Increased body weight, even at 22 months after the inter-
vention, was higher (p = 0.004) in sham-operated rats
compared to portal hypertensive-rats (Table 1).
Cholesterol, Triglycerides and proteins increased in the 
liver of portal hypertensive-rats
The liver content of Cholesterol (p < 0.001), Triglycerides
(p < 0.01) and proteins (p < 0.001) increased in rats with
portal hypertension compared to sham-operated rats (Fig-
ure 1).
Serum cholesterol, Triglycerides, LDL and LBP increased 
and HDL decreased in rats with portal hypertension
Serum levels of Cholesterol, Triglycerides (p < 0.01), LDL
(p < 0.001) and LBP (p < 0.001) increased in portal hyper-
tensive-rats while HDL decreased (p < 0.001) (Figures 2
and 3).
Serum Insulin and Somatostatin decreased in rats with 
portal hypertension
In rats with portal hypertension, serum glucose levels did
not show differences in relation to sham-operated (Figure
3). On the contrary, Insulin and Somatostatin levels
tended to decrease in portal hypertensive-rats (Figure 3).
Discussion
Long-term portal hypertension (PH) in the rat shows per-
sistent splanchnic alterations related to portal hyperpres-
sure and produces changes in the metabolism of lipids
and carbohydrates that could be involved in the develop-
ment of liver steatosis, as well as in some of the manifes-
tations described in the clinical Metabolic Syndrome
(MS). Thus, in rats with PH by triple partial portal vein
ligation (TPVL) we have demonstrated that triglycerides
(TG) and Cholesterol increase in the liver. In the serum,
levels of LDL and LBP also increase whereas TG, choles-
terol, HDL and Somatostatin decrease.
Partial portal vein ligation (PVL) in various animals, but
particularly in the rat, has widely been used for the study
of PH [4,5]. Although this experimental model is nor-
mally used to study short-term changes (15–30 days after
the operation), the study of its late evolutive phases could
be considered of greater interest since the mechanisms
involved in its production, as well as in the related com-
plications, would be more similar to those found in
chronic liver disease in humans [1-3] since they are related
to the chronicity of PH, among other factors. In this study,
the rats showed portal hyperpressure, liver atrophy,
splenomegaly and portal-systemic collateral vessels. The
persistence of these splanchnic changes related to PH in
rats at almost 2 years (22 months) after the operation
reinforces the idea that triple partial portal vein ligation in
the rat is an experimental model which maintains its
validity even in very late states. Interestingly enough, the
mean life of male Wistar rats is approximately 2.7 years
and inbred rats, like we have used in this study, indeed
have shorter life spans.
We have already demonstrated in earlier (1 month and 1
year after the operation) periods, that rats with prehepatic
PH by TPVL suffer a progressive liver fatty steatosis with
megamitochondria formation [6,7] and an increased
hepatic synthesis of free fatty acids (FFA), diacylglicerol
and Triglycerides (TG) [8]. This upregulation of the lipid
hepatic synthesis was associated with an increase in the
liver content of cholesterol [8]. In the present study we
have shown that in portal hypertensive-rats at long-term
evolution, close to 2 years, the impairment of the lipid
metabolism persists. Thus, these rats present an increase
Table 1: 
SO (n = 10) PH (n = 9) p value
PP (mmHg) 9.25 ± 1.78 11.98 ± 1.72 0.004
SW (g) 1.26 ± 0.19 1.38 ± 0.35 NS
SW/BW ×100 0.19 ± 0.02 0.30 ± 0.06 0.0001
BWI (g) 401.59 ± 79.22 277.55 ± 82.95 0.004
BWI (%) 262.46 ± 30.62 211.02 ± 33.18 0.003
LW (g) 17.11 ± 2.46 12.55 ± 1.79 0.0001
PLLW (g) 5.84 ± 0.74 4.99 ± 0.99 0.03
PLLW (%) 35.76 ± 4.20 39.63 ± 4.67 NS
ALLW (g) 11.02 ± 1.93 7.55 ± 1.10 0.0001
ALLW (%) 64.24 ± 4.20 60.36 ± 4.67 NS
LW/BW × 100 2.62 ± 0.28 2.42 ± 0.22 NS
TW (g) 3.81 ± 0.35 3.22 ± 0.49 0.008
TW/BW ×100 0.60 ± 0.07 0.63 ± 0.16 NS
Mean ± SD; Portal pressure (PP), spleen weight (SW), spleen weight/
body weight (SW/BW) ratio, body weight increase (BWI), liver weight 
(LW), posterior liver lobes (PLL: middle and left lateral lobes) weight; 
anterior liver lobes (ALL: right lateral and caudate lobes) weight, liver 
weight/body weight (LW/BW) ratio, testes weight (TW) and testes 
weight/body weight (TW/BW) ratio in sham-operated (SO) and 
portal hypertensive (PH) rats.Page 3 of 10
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with serum lipid levels changes. Particularly, LDL and LBP
increase whereas TG, Cholesterol and HDL decrease.
The sequence of events in NAFLD generally begins as
hepatic steatosis, continues with steatohepatitis, and ends
with cirrhosis and liver cancer [23]. Although a progres-
sive hepatocytic fatty infiltration occurs during chronic
evolution in TPVL-rats, this does not coexist with inflam-
mation and/or fibrosis [6,8]. Therefore, hepatic steatosis
developing in PH-rats could be considered a "benign" ini-
tial type of the broad spectrum of NAFLD [24].
Hepatic steatosis results from a relative increase in TG for-
mation vs. Turnover. TG formation is, in turn, dependent
on the availability of FFAs [24]. One of the new findings
to emerge is that omental and mesenteric fat storage cells
constitute a major endocrine influence on the liver and
that the imbalance of their adipokines (e.g. leptin, adi-
ponectin, visfatin, apelin and resistin) induces hepatic fat
deposition, insulin resistance (IR) and progression to
NASH [22,25]. Therefore, in rats with PH, increased lipol-
ysis in fat-swollen mesenteric fat cells results in an espe-
cially large increase in the FFA pool entering the portal
circulation and being delivered directly to the liver [26].
FFAs, after being uptaken by hepatocytes, can be oxidized
as fuel [25] but when there is an excess of FFAs, they are
transformed into TG, which are then stored [25]. So, high
amounts of FFAs, neurohumoral and pro-inflammatory
mediators, particularly TNF-a, which is increased in por-
tal-hypertensive rats [16,27], will hit the liver inducing
inflammation and steatosis [28]. Thus, TNF- a is now
highlighted as a key factor in the interaction between fat
storage, insulin action and inflammation[29].
Cholesterol, Triglycerides (TG) and Phospholipids (PL) liver content in sham-operated (SO; n = 10) and portal hypertensive (PH; n = 9) ratsFigure 1
Cholesterol, Triglycerides (TG) and Phospholipids (PL) liver content in sham-operated (SO; n = 10) and portal 
hypertensive (PH; n = 9) rats. The results are represented as the mean ± the Standard Deviation. **p < 0.01; ***p < 0.001: 
statistically significant value in relation to the SO Group.Page 4 of 10
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swollen mesenteric and omental adipocytes and the
hepato-intestinal release of pro-inflammatory mediators
[7,16,30], other alterations like intestinal mucosa hypoxia
with oxidative and nitrosative stress, the intestinal layer
infiltration by mast cells [13] and intestinal bacterial
translocation [31] stand out between the splanchnic fac-
tors probably related to the development of hepatic stea-
tosis in rats with PH.
An increasing body of scientific research confirms the role
of mastocytes in the pathogenesis of inflammatory and
immunes diseases, such as the metabolic syndrome [32].
Recently metabotropic effects have been attributed to
mast cells since they take part in carbohydrate and lipid
metabolism [32] by decreasing the sensitivity of the liver
receptors to insulin [32]. Furthermore, rat Chymase or Rat
Mast Cell Protease-II (RMCP-II), which is increased in the
serum and mesenteric lymph nodes in portal hyperten-
sive-rats [15], is able to convert Angiotensinogen into
Angiotensin-II (Ang II) [33]. Ang-II, in turn, initiates the
gene expression of multiple pro-inflammatory mediators,
interrupts the anti-inflammatory effects of Insulin [34],
promotes IR [35] and stimulates the release of leptin, a
prothrombotic and pro-inflammatory cytokine that acti-
vates an array of immune functions [36].
We have shown that in rats with short- and long-term por-
tal hypertension, the balance between the different bacte-
ria strains changes and is associated with bacterial
overgrowth and BT to mesenteric lymph nodes [31]. Gut-
derived endotoxin may induce steatohepatitis through
Cholesterol, Triglycerides (TG), low-density lipoproteins (LDL) and high-density lipoproteins (HDL) serum concentrations in sham-operated (SO; n = 10) and portal hypertensive (PH; n = 9) ratsFigure 2
Cholesterol, Triglycerides (TG), low-density lipoproteins (LDL) and high-density lipoproteins (HDL) serum 
concentrations in sham-operated (SO; n = 10) and portal hypertensive (PH; n = 9) rats. The results are repre-
sented as the mean ± the Standard Deviation. **p < 0.01; ***p < 0.001: statistically significant value in relation to the SO 
Group.Page 5 of 10
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production of Resistin, which in turn leads to IR [36]. The
administration of probiotics to ob/ob mice, a model of
NAFLD, led to improvement in steatosis, hepatomegaly
and NF-κB activity [36,37].
When Chronic Phase Response (CFR) is developed by the
body, in response to chronic stress situations, such as
long-term PH, hyperlipemia, increased lipolysis of vis-
ceral fat with release of FFAs and liver IR is induced [38].
In addition, the liver increases the synthesis of Acute
Phase Proteins (APP), including LPS binding protein
(LBP), whose serum levels are markedly increased in rats
with PH. LBP is a very sensible host mechanism that rec-
ognizes Gram-negative bacterial LPS, binds it and acts as
an opsonin, enhancing bacterial phagocytosis [39]. There-
fore, in chronic PH-rats, which develop a low-grade
inflammatory response and which have an overgrowth of
intestinal anaerobic bacteria [31], both the liver and the
gut would increase the production of this important
defense molecule.
In acute and chronic inflammation, infection, sepsis and
MS, there is an impairment in lipid and lipoprotein
metabolism, with an increase in TG, LDL and LBP and a
marked decrease of HDL [40,41]. Interestingly enough,
our rats with chronic portal hypertension show similar
changes in lipid and lipoprotein metabolism to those pre-
sented by humans with sepsis or MS. One important orig-
inal result in this study is that HDL was dramatically
reduced in portal hypertensive rats and this would have
important deleterious consequences. Thus, the ability of
Glucose, Insulin, Somatostatin (STH) and Lipid Binding Protein (LBP) serum concentrations in sham-operated (SO; n = 10) and portal hyperte sive (PH; n = 9) ratsFigure 3
Glucose, Insulin, Somatostatin (STH) and Lipid Binding Protein (LBP) serum concentrations in sham-oper-
ated (SO; n = 10) and portal hypertensive (PH; n = 9) rats. The results are represented as the mean ± the Standard 
Deviation. ***p < 0.001: statistically significant value in relation to the SO Group.Page 6 of 10
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anti-inflammatory and anti-oxidant properties of HDL
[39,42,43] would also be inhibited.
It is now accepted that NAFLD is the hepatic manifesta-
tion of MS and it results from IR [35]. It is true that in
these rats with chronic PH, serum Insulin is not increased.
Indeed, Insulin levels are lesser in portal hypertensive-rats
than in the sham-operated, but this could be a conse-
quence of their chronic evolution. In NAFLD, increased
FFA uptake by the liver results in hepatic glucose output,
which is balanced by pancreatic islet β cells insulin pro-
duction [44]. Perhaps, in these rats, a pancreatic exhaus-
tion related to islet cell apoptosis by FFAs [44] is produced
two years after the intervention and therefore β cells are
unable to produce enough Insulin.
It is becoming increasingly evident that NAFLD can occur
in the absence of overt IR [23]. In a similar way, the liver
fat storage in rats with chronic PH accumulate lipids in
their liver. This lipid storage would be mostly due to both
factors, the increased support of FFAs from the inflamed
splanchnic area and the inhibited FFAs liver oxidation,
more than to IR.
The neuroendocrine response to stress and the existence
of a systemic chronic inflammation would be another link
between disordered lipid metabolism, inflammation and
IR in the evolution of this experimental model. Kelley et
al. [45] have proposed the idea that metabolic inflexibil-
ity, i.e., an impaired capacity to appropriately switch
between "fed" (predominantly carbohydrate metabo-
lism) and "fasting" (predominantly lipid oxidation
metabolism) typifies IR and obesity. This mismatching
between energy supply and demand may contribute to the
accumulation of ectopic lipid, particularly in liver over-
time [45]. In a similar way, the rats with long-term PH,
and therefore, with subclinical chronic low-grade inflam-
mation, inappropriately switch carbohydrate metabolism
to a predominant lipid metabolism, inducing body
energy imbalance and ultimately hepatic steatosis.
Thus, in long-term portal hypertensive-rats, the liver
parenchyma seems to progressively convert into fat. Inter-
estingly enough, from an embryologic point of view the
liver develops in close association with the yolk sac [45]
and could play a key role as an intermediary for lipid
metabolism between the yolk sac and the fetus. The yolk
sac is a vital player in providing lipids (cholesterol, HDL
and VLDL) and lipid-soluble nutrients to the embryos
during early phases of the development [46]. In experi-
mental PH, the liver could function as a kind of yolk sac
in which a pathological storage of lipids and lipid-soluble
hormones and/or neuropeptides are produced in order to
maintain metabolic homeostasis.
Conclusion
Dyslipemia and hepatic steatosis would represent under-
lying factors of prehepatic portal hypertension in the rat
which would be a chronic low-grade inflammatory state
similar to that presented by the human being with acute
and/or chronic inflammatory responses, i.e., infection,
sepsis, NAFLD and metabolic syndrome.
Methods
Animals
Male Wistar rats, with average body weights of 250 g, from
the Vivarium of the Complutense University of Madrid,
were used. The animals were fed a standard laboratory
rodent diet (rat/mouse A04 maintenance diet, Panlab,
Spain: 17.6% proteins, 43.3% starch, 2.5% lipids) and
water ad libitum. They were housed in a light/dark-control-
led room, with an average temperature (22 ± 2°C) and
humidity (65–70%) in groups of three to four animals.
All the studies were approved by the Complutense Univer-
sity Ethical Committee and adhered to the guidelines of
the Commission Directive 86/609/EEC (The Council
Directive of the European Community) concerning the pro-
tection of animals used for experimental and other scien-
tific purposes. The National legislation, in agreement with
this Directive, is defined in Royal Decree n° 1202/2005.
Experimental Design
The animals were randomly divided into two groups:
Group I (n = 10), sham-operated rats, and Group II (n =
9), consisted in rats with prehepatic portal hypertension
by triple partial portal vein ligation (TPVL).
Surgical Techniques
The animals were anesthetized by i.m. injection of Keta-
mine (100 mg/kg) and Xylacine (12 mg/kg). A midline
abdominal incision was made and the portal vein was
only dissected in the sham-operated (SO) animals. The
surgical procedure to produce portal hypertension by tri-
ple partial ligation of the portal vein has been described
previously [17]. In brief, the portal vein was isolated and
three ligatures, fixed on a sylactic guide, were performed
in its superior, middle and inferior portions. The stenoses
were calibrated by a simultaneous ligation (4-0 silk)
around the portal vein and a 20-gauge blunt-tipped nee-
dle. The midline incision was closed in two layers with an
absorbable suture (Polyglycolic acid) and 3-0 silk. Analge-
sia was maintained during 24 hours with Buprenorphine
(0.05 mg/8 h s.c.).
All the animals were sacrificed by exanguination through
the inferior vena cava 22 months after the operation. Pre-
viously, the rats of both groups were anesthetized by i.m.
injection of Ketamine (100 mg/kg) and Xylacine (12 mg/
kg), a midline abdominal incision was made and portalPage 7 of 10
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thy and collateral circulation were studied. Finally, a sam-
ple (50 mg) of the middle lobe of the liver was rapidly
frozen in acetone, chilled with dry ice and stored at -80°C
until the lipid assays.
Portal Pressure Measurement
Splenic pulp pressure, an effective indirect measurement
of portal pressure (PP), was measured by inserting a 20-
gauge fluid-filled needle into the spleen parenchyma. The
needle was joined to a PE-50 tube, then connected to a
pressure recorder (PowerLab 200 ML 201) and a trans-
ducer (Sensonor SN-844) with a Chart V4.0 computer
program (ADI Instruments), and finally calibrated before
each experiment.
Mesenteric venous vasculopathy study
Mesenteric venous vasculopathy, a characteristic feature
of splanchnic venous congestion, is shown as dilation and
tortuosity of the superior mesenteric vein branches.
Portosystemic collateral circulation study method
Portosystemic collateral circulation was studied as fol-
lows. First, a midline abdominal incision with a large
bilateral subcostal extension was performed and then the
areas in which the collateral venous circulation was devel-
oped, i.e. the splenorenal, gastroesophageal, colorectal
and hepatic hilum, were carefully studied for the presence
of increased collateral veins.
Serum Assays
Blood samples were drawn by puncturing the infrahepatic
inferior vena cava. After 15 minutes of centrifugation at
1,500 g, the serum was transferred to polypropylene tubes
and then frozen at -42°C until lipids, lipoproteins, LBP,
glucose, Insulin and Somatostatin were assayed.
The serum levels of cholesterol, Triglycerides, HDL and
LDL lipoproteins were measured by spectrophotometric
colorimetric techniques, according to the manufacturer
instructions (SpinReact, SA, Gerona, Spain).
Cholesterol determination was performed with a specific
kit (SpinReact) based on the action of the enzyme choles-
terol sterase which hydrolyzed the esters present in the
sample, giving free cholesterol and fatty acids [47]. A sub-
sequent enzymatic oxidation using the cholesterol
enzyme oxidase formed hydrogen peroxide and cholester-
ine. The peroxide was evaluated by the Trinder reaction by
a chromogene, in the presence of peroxidase, forming a
quinonimine with a red coloring. The intensity of this
color was proportional to the cholesterol concentration in
the sample. Finally, colorimetric determination was per-
formed in a spectrophotometer (Eppendorf, model Bio-
photometer) at a wavelength of 500 nm.
Triglyceride determination was performed with a specific
kit (SpinReact) based on the action of the enzyme lipo-
proteinlipase with liberation of glycerol and free fatty
acids. Glycerol is converted into glycerol-3-phosphate and
adenosine-5-diphosphate by glycerol kinase and ATP.
Glycerol-3-phosphate is then converted by glycerol phos-
phate dehydrogenase into didihydroxyacetone phosphate
and hydrogen peroxide. In the last reaction, hydrogen per-
oxide reacts with 4-aminophenazone and p-clorophenol
in presence of peroxidase to give a red colored dye. The
intensity of the color formed is proportional to the triglyc-
eride concentration in the sample [48]. Finally, colorimet-
ric determination was performed in a spectrophotometer
(Eppendorf, model Biophotometer) at a wavelength of
505 nm.
HDL-Cholesterol determination was performed with a spe-
cific kit (SpinReact) based on the action of a product
which induces the precipitation of the LDL- and VLDL-
lipoproteins. Thus, the HDL-lipoproteins are only iso-
lated in the supernatant, in which the binding of choles-
terol is then measured [49]. Finally, colorimetric
determination was performed in a spectrophotometer
(Eppendorf, model Biophotometer) at a wavelength of
500 nm.
LDL-Cholesterol determination was performed with a spe-
cific kit (SpinReact), with a two-step technique. First, chy-
lomicrons, VLDL and HDL are eliminated as cholesterol.
This cholesterol, specifically derived from these lipopro-
teins, but not from LDL, is oxidated to colesterine and
hydrogen peroxide and, then degradated to catalase. In a
second reaction, LDL is specifically measured through the
action of peroxidase with the formation of pinkish color
quinine. The intensity of the color formed is proportional
to the LDL concentration in the sample [49]. Finally,
colorimetric determination was performed in a spectro-
photometer (Eppendorf, model Biophotometer) at a
wavelength of 600 nm.
LBP serum levels were assayed by the ELISA technique
with a specific test for rodents (Hbt mouse LBP ELISA test
kit, HyCult Biotechnology b.v., The Netherlands). The kit
has a minimum detection level of 0.4 ng/ml and a meas-
urable concentration range of 0.4 to 100 ng/ml.
Glucose serum levels were measured with an enzymatic
technique based on the action of Glucose Oxidase (Sigma,
Saint Louis, Missouri, USA). In brief, glucose is oxidized
to gluconic acid and hydrogen peroxide by glucose oxi-
dase. Hydrogen peroxide reacts with o-dianisidine in the
presence of peroxidase to form a colored product. Oxi-
dized o-dianisidine reacts with sulfuric acid to form a
more stable colored product. The intensity of the pinkPage 8 of 10
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glucose concentration [50].
Insulin and somatostatin were measured by RIA with our
own specific antibody [51]. Tyr2-somatostatin was radio-
iodinated by the lactoperoxidase method [52]. Purifica-
tion was performed using ion-exchange chromatography
[53]. The sensitivity of the assay was 0.032 ± 0.002 pg/
tube (n = 7). The intraassay variation ranged from 8.7%
(lower part of the standard curve) to 2.1 % (middle) and
6.2% (upper). The interassay variation oscillated between
6.1 and 8.9%.
Liver Assays
After specific extraction, TG, cholesterol, phospholipids
and proteins were determined.
After the addition of 1.0 ml of chlorophorm/methanol
(2:1) to the tubes containing the liver samples, the con-
tent was homogenized and centrifuged (0°C). TG, choles-
terol and phospholipids were then measured by the same
spectrophotometric colorimetric techniques described for
the serum lipids (SpinReact, SA, Gerona, Spain).
The liver protein concentrations were determined by the
colorimetric method described by Bradford [54]. This
method is based on the binding of Coomassie Blue to pro-
teins. This binding causes a displacement of the peak
absorption of the dye from 465 to 595 nm. Absorbance is
measured in the samples at the latter wavelength against a
known reference curve. The protein complex dye has a
high coefficient of extinction, which gives it a high sensi-
tivity at measuring the protein. Protein determination was
carried out because the concentration of TG, phospholip-
ids and cholesterol is expressed in relation to the concen-
tration of liver proteins.
Statistical Analysis
Statistical analyses were performed using SPSS software
(Statistical Package for the Social Sciences, version 14.00).
The results are expressed as the mean ± standard devia-
tion. Student t-test for independent data were used for
comparison of the variables between the two groups stud-
ied. The results were considered significant if p < 0.05.
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